This NDC is on FDA's drug shortage list (posted Dec 22, 2021)
Reported reason: Discontinuation of the manufacture of the drug
Product Information
RIFAMPIN 300 MG CAPSULE is a generic product labeled by Epic Pharma LLC, priced at $0.6802 per EA under NDC 42806079901. Its NADAC has been published 216 times since Jul 6, 2022.
FDA first approved this application on May 28, 1997. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Epic Pharma LLCNDC
42806079901
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
RIFAMPINApproval Type
Generic (ANDA)
FDA Application
ANDA064150FDA Approved
5/28/1997
TE Code
AB
On Market Since
12/15/2021
Pharmacological Classes
Price Statistics
The NADAC for RIFAMPIN 300 MG CAPSULE has been published 216 times since Jul 6, 2022, and over the history we have for it it has declined 3.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6802 per EA |
|---|---|
| All-time high | $0.7501 (Dec 14, 2022) |
| All-time low | $0.4888 (Nov 20, 2024) |
| 52-week high | $0.7186 |
| 52-week low | $0.6802 |
| Median price | $0.6910 |
| Average price | $0.6790 |
| Largest weekly change | -26.5% (Nov 20, 2024) |
| Weeks tracked | 216 |
| Tracking since | Jul 6, 2022 |
1W
N/A
1M
N/A
3M
-1.3%
6M
-0.9%
1Y
-3.4%
3Y
+2.1%
5Y
N/A
All
-3.9%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Epic Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rifampin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Rifamycin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIFAMPIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIFAMPIN 300 MG CAPSULE, manufactured by Epic Pharma LLC, is $0.6802 per EA (NDC 42806079901), effective Aug 19, 2026.
How has the price of RIFAMPIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIFAMPIN 300 MG CAPSULE has declined 3.9%. It has been tracked across 216 weekly CMS publications since Jul 6, 2022.
What are the highest and lowest recorded NADAC prices for RIFAMPIN 300 MG CAPSULE?
Since Jul 6, 2022, the NADAC for RIFAMPIN 300 MG CAPSULE has ranged from a low of $0.4888 (Nov 20, 2024) to a high of $0.7501 (Dec 14, 2022), with a median of $0.6910 per EA.
Are there cheaper alternatives to RIFAMPIN 300 MG CAPSULE?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RIFAMPIN 300 MG CAPSULE, is $0.6789 per EA — about 0% below RIFAMPIN 300 MG CAPSULE.
Who manufactures RIFAMPIN 300 MG CAPSULE?
RIFAMPIN 300 MG CAPSULE (NDC 42806079901) is labeled by Epic Pharma LLC, and CMS classifies it as a generic product.
Is RIFAMPIN 300 MG CAPSULE in shortage?
Yes — NDC 42806079901 is currently listed in FDA's drug shortage database (posted Dec 22, 2021). Reported reason: Discontinuation of the manufacture of the drug.